Starpharma Holdings Ltd - Asset Resilience Ratio

Latest as of December 2025: 69.74%

Starpharma Holdings Ltd (SPL) has an Asset Resilience Ratio of 69.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$18.25 Million
≈ $12.91 Million USD Cash + Short-term Investments

Total Assets

AU$26.17 Million
≈ $18.51 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Starpharma Holdings Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Starpharma Holdings Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Starpharma Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Starpharma Holdings Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$18.25 Million 69.74%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$18.25 Million 69.74%

Asset Resilience Insights

  • Very High Liquidity: Starpharma Holdings Ltd maintains exceptional liquid asset reserves at 69.74% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Starpharma Holdings Ltd Industry Peers by Asset Resilience Ratio

Compare Starpharma Holdings Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 57.90%
TELIX Pharmaceuticals Ltd
AU:TLX
Biotechnology 32.29%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 2.34%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%

Annual Asset Resilience Ratio for Starpharma Holdings Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Starpharma Holdings Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 59.40% AU$15.10 Million
≈ $10.68 Million
AU$25.42 Million
≈ $17.99 Million
-2.61pp
2024-06-30 62.01% AU$22.83 Million
≈ $16.15 Million
AU$36.81 Million
≈ $26.05 Million
-2.34pp
2023-06-30 64.35% AU$33.52 Million
≈ $23.72 Million
AU$52.09 Million
≈ $36.85 Million
-4.85pp
2022-06-30 69.20% AU$45.79 Million
≈ $32.40 Million
AU$66.17 Million
≈ $46.82 Million
-9.04pp
2021-06-30 78.24% AU$57.30 Million
≈ $40.54 Million
AU$73.24 Million
≈ $51.82 Million
+11.74pp
2020-06-30 66.49% AU$25.98 Million
≈ $18.39 Million
AU$39.08 Million
≈ $27.65 Million
-11.91pp
2019-06-30 78.40% AU$38.31 Million
≈ $27.10 Million
AU$48.86 Million
≈ $34.57 Million
-3.58pp
2018-06-30 81.98% AU$47.97 Million
≈ $33.94 Million
AU$58.51 Million
≈ $41.40 Million
-4.88pp
2017-06-30 86.85% AU$57.84 Million
≈ $40.92 Million
AU$66.59 Million
≈ $47.12 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$59.04 Million
≈ $41.77 Million
--
pp = percentage points

About Starpharma Holdings Ltd

AU:SPL Australia Biotechnology
Market Cap
$238.27 Million
AU$336.74 Million AUD
Market Cap Rank
#15880 Global
#434 in Australia
Share Price
AU$0.80
Change (1 day)
+6.67%
52-Week Range
AU$0.10 - AU$0.80
All Time High
AU$2.49
About

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more